<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284503</url>
  </required_header>
  <id_info>
    <org_study_id>ISSCRES0169</org_study_id>
    <nct_id>NCT02284503</nct_id>
  </id_info>
  <brief_title>Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)</brief_title>
  <official_title>A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 30-day, randomized, open-label, 3-arm, parallel-group, multicenter study exploring
      efficacy of intensive rosuvastatin treatment peri-PCI in Chinese patients with NSTE-ACS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non ST-segment elevated acute coronary syndrome(NSTE-ACS) is increasing rapidly, and is more
      frequent than ST-segment elevated acute coronary syndrome (STE-ACS) now. NSTE-ACS patients
      sent to early PCI procedure is large and increasing rapidly in China.Quite a few trials have
      focused on high loading dose statin before PCI to improve cardiovascular outcomes in ACS. In
      Asian, high loading dose statin therapy showed different outcome. Rosuvastatin (RSV) is one
      of the most potent statins.Nowadays, quite a few experts think ACS patients undergoing PCI
      not only need loading dose statin, but also post PCI intensive statin treatment is rather
      important. Chinese consensus and western guidelines recommend intensive statin treatment in
      these patients. However, Chinese consensus referred to the western study as there's no
      relevant intensive statin treatment peri-PCI study in China until now.

      Thus this study is designed to explore the efficacy of intensive statin treatment peri-PCI
      (early loading dose-RSV 40 mg or 20mg before PCI and subsequent 20mg post PCI) in
      periprocedural myocardial injury and 30 days MACE reduction in Chinese NSTE-ACS patients and
      explore efficacy of 30-day RSV 20 mg post-PCI treatment in lipid profile, inflammatory
      factors compared with baseline.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial injury reduction</measure>
    <time_frame>30 days</time_frame>
    <description>Myocardial injury assessed by creatine kinase-MB. (CK-MB) elevation, defined as a post-procedural elevation of CK-MB values &gt;3×99th percentile Upper Reference Limit (URL) in patients with normal baseline values &gt;99th percentile URL or a rise of CK-MB values&gt;20% if the baseline values are elevated and are stable or falling; or assessed by cTn elevation, defined as a post-procedural elevation of cardiac troponin (cTn) values &gt;5×99th percentile URL in patients with normal baseline values &gt;99th percentile URL or a rise of cTn values&gt;20% if the baseline values are elevated and are stable or falling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE reduction</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Cardiac Events(MACE) event including death, Myocardial infarction(MI), target vessel revascularization, ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of lipid</measure>
    <time_frame>30 days</time_frame>
    <description>the change of lipid marker, including Low-density lipoprotein cholesterol(LDL-C), total cholesterol(TC), High-density lipoprotein cholesterol(HDL-C), triglyceride(TG), non-HDL-C, between Rosuvastatin 10 mg/day and 20 mg/day treatment at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of hsCRP</measure>
    <time_frame>30 days</time_frame>
    <description>The change of inflammatory marker High sensitivity C-reactive protein(hsCRP) between Rosuvastatin 10 mg/day and 20 mg/day treatment at 30 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Non-ST-elevation Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>40mg Rosuvastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg Rosuvastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no statin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>The subjects will receive intensive Rosuvastatin before and after PCI</description>
    <arm_group_label>40mg Rosuvastatin group</arm_group_label>
    <arm_group_label>20mg Rosuvastatin group</arm_group_label>
    <arm_group_label>no statin group</arm_group_label>
    <other_name>Rosuvastatin Calcium Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 year old males and non-child-bearing period females.

          2. Clinical diagnosed with NSTE-ACS, including unstable angina or non-ST-segment
             elevation myocardial infarction(NSTEMI).

               -  For unstable angina, the diagnose should meet all below:

             Clinical onset features: angina for at least 20 min when resting; initial onset angina
             pectoris(new onset within one month) manifests spontaneous angina or labor angina (CCS
             grade II or III); Symptoms of original stable angina pectoris aggravate in one month
             and at least achieve CCS grade III (accelerated angina pectoris); angina onset within
             one month after MI.

             ECG: At least twice in one month: ST depression or elevation &gt;0.1millivolt (mv) or
             T-wave inversion ≥0.2 mv in 2 or more contiguous electrocardiographic leads when onset
             and the ST-T changes recovered after remission of chest pain. Myocardial damage marker
             do not elevate or reach the MI diagnostic level.

               -  For NSTEMI, the diagnose should meet all below ischemia symptoms(ischemic chest
                  pain lasting more than 30 min and cannot relief significantly by sub-lingual NTG)
                  ECG change: new ST-T dynamic development (new or transient ST depression ≥0.1mv
                  or T-wave inversion≥0.2mv).

             Myocardial damage marker level is normal or elevated to the MI diagnostic level.

          3. Received early (within 48 h) Percutaneous Coronary Intervention(PCI).

          4. Should be statin- naïve(last 3 months).

          5. Only receive drug-eluting stents.

          6. Sign the Informed Consent Form(ICF)

        Exclusion Criteria:

        Any of the following is regarded as a criterion for exclusion from the study:

          1. Diagnosis as STEMI;

          2. NSTE-ACS with high-risk features warranting emergency coronary angiography;

          3. Receive only medical therapy or Coronary Artery Bypass Graft(CABG)

          4. Active liver disease or dysfunction including agnogenic serum transaminase sustained
             elevation or higher than 3 times upper limit of normal(ULN);

          5. Left ventricular ejection fraction＜30%;

          6. Previous or current treatment with statins;

          7. Patients with myopathy or serum creatine kinase &gt; 5 times the upper limit of normal
             not caused by myocardial injury;

          8. Severe renal function damage (creatinine clearance rate&lt;30 ml/min);

          9. Severe anemia (haemoglobin&lt; 6g/L);

         10. Diagnosed with malignancy within 5 years;

         11. Concurrent use ciclosporin；

         12. Investigator evaluated as not appropriate for statins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yinman Wang, Master</last_name>
    <phone>+86 21 64041990</phone>
    <phone_ext>2521</phone_ext>
    <email>wang.yinman@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yinman Wang, Master</last_name>
      <phone>+86 21 64041990</phone>
      <phone_ext>2521</phone_ext>
      <email>wang.yinman@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Junbo Ge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010 Jun 10;362(23):2155-65. doi: 10.1056/NEJMoa0908610.</citation>
    <PMID>20558366</PMID>
  </results_reference>
  <results_reference>
    <citation>Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004 Aug 10;110(6):674-8. Epub 2004 Jul 26.</citation>
    <PMID>15277322</PMID>
  </results_reference>
  <results_reference>
    <citation>Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010 Sep 28;56(14):1099-109. doi: 10.1016/j.jacc.2010.04.023. Epub 2010 Aug 31. Review.</citation>
    <PMID>20825761</PMID>
  </results_reference>
  <results_reference>
    <citation>Yun KH, Oh SK, Rhee SJ, Yoo NJ, Kim NH, Jeong JW. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2011 Jan 7;146(1):68-72. doi: 10.1016/j.ijcard.2010.04.052. Epub 2010 May 14.</citation>
    <PMID>20471117</PMID>
  </results_reference>
  <results_reference>
    <citation>Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim NH, Ahn YK, Jeong JW. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009 Nov 12;137(3):246-51. doi: 10.1016/j.ijcard.2008.06.055. Epub 2008 Aug 15.</citation>
    <PMID>18706705</PMID>
  </results_reference>
  <results_reference>
    <citation>Gao yuan et al. Comparison of Effects of Loading Dose Rosuvastatin VERSUS Atorvastatin Therapy in Non-ST Segment Elevation Acute Coronary Syndrome Patients. Journal of China Medical University. 2013; 42:235-239.</citation>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MI reduction</keyword>
  <keyword>intensive statin treatment</keyword>
  <keyword>NSTE-ACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

